Peripheral Embolic Protection Devices Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Peripheral Embolic Protection Devices Pipeline Market Report Overview

Peripheral Embolic Protection Devices are used to capture and remove plaque debris that is dislodged during interventional procedures. Peripheral Embolic Protection Devices used in the lower extremity, carotid, and renal arteries are included here.

The Peripheral Embolic Protection Devices pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials.

Key Territories ·       The United States

·       China

·       Europe

·       Hong Kong

·       Israel

Key Segments ·       Carotid-specific Embolic Protection Devices

·       Carotid and Lower Extremity Embolic Protection Devices

Key Regulatory Paths ·       510(k)

·       CE

·       NMPA

·       PMA

·       TGA

Leading Companies ·       Abbott Vascular Inc

·       AorticLab Sarl

·       APT Medical Inc

·       Artio Medical

·       Avantec Vascular Corp

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Peripheral Embolic Protection Devices Pipeline Market Segments

A few of the key segments in the Peripheral Embolic Protection Devices pipeline market are Carotid-specific Embolic Protection Devices and Carotid and Lower Extremity Embolic Protection Devices. As of August 2024, Carotid-specific Embolic Protection Devices had the highest number of Peripheral Embolic Protection Devices pipeline products.

Peripheral Embolic Protection Devices Pipeline Market Analysis by Segments, 2024 (%)

Peripheral Embolic Protection Devices Pipeline Market Analysis by Segments, 2024 (%)

Buy the Full Report for More Segments Insights into the Peripheral Embolic Protection Devices Pipeline Market

Download a Free Report Sample

Peripheral Embolic Protection Devices Pipeline Market Segmentation by Territories

A few of the key territories with the Peripheral Embolic Protection Devices pipeline market are Europe, the United States, Global, and Israel among others. As of August 2024, the US had the highest number of Peripheral Embolic Protection Devices pipeline products.

Peripheral Embolic Protection Devices Pipeline Market Analysis by Territories, 2024 (%)

Peripheral Embolic Protection Devices Pipeline Market Analysis by Territories, 2024 (%)

Buy the Full Report for More Territory Insights into the Peripheral Embolic Protection Devices Pipeline Market

Download a Free Report Sample

Peripheral Embolic Protection Devices Pipeline Market Segmentation by Regulatory Paths

A few of the key regulatory paths in the Peripheral Embolic Protection Devices pipeline products market are PMA, CE, NMPA, MDL, and 510(k) among others. As of August 2024, 510(k) was the most followed pathway for pipeline products in the Peripheral Embolic Protection Devices market.

Peripheral Embolic Protection Devices Pipeline Market Analysis by Regulatory Paths, 2024 (%)

Peripheral Embolic Protection Devices Pipeline Market Analysis by Regulatory Paths, 2024 (%)

Buy the Full Report for More Regulatory Path Insights into the Peripheral Embolic Protection Devices Pipeline Market

Download a Free Report Sample

Peripheral Embolic Protection Devices Pipeline Market – Competitive Landscape

A few of the key companies associated with the Peripheral Embolic Protection Devices pipeline market are Abbott Vascular Inc., AorticLab Sarl, APT Medical Inc., Artio Medical, and Avantec Vascular Corp among others.

Abbott Vascular Inc: Abbott Vascular, formerly Perclose, Inc., a subsidiary of Abbott Laboratories, is a medical device company that develops manufactures and markets cardiovascular devices. The company offers coronary intervention, peripheral intervention, and structural heart products. Its coronary intervention products include coronary dilatation catheters, coronary drug-eluting stents, coronary guide wires, and others.

Abbott Vascular’s peripheral intervention products comprise peripheral guide wires, dilatation catheters, guiding catheters, and stent grafts. The company provides minimally invasive treatment for mitral regurgitation and other structural defects of the heart. It also offers education and training services for healthcare professionals. Abbott Vascular is headquartered in Santa Clara, California, the US.

Peripheral Embolic Protection Devices Pipeline Market Analysis by Companies, 2024
Peripheral Embolic Protection Devices Pipeline Market Analysis by Companies, 2024Buy the Full Report for More Company Insights into the Peripheral Embolic Protection Devices Pipeline Market
Download a Free Report Sample

Segments Covered in the Report

Peripheral Embolic Protection Devices Pipeline Market Segments Outlook (2024)

  • Carotid-specific Embolic Protection Devices
  • Carotid and Lower Extremity Embolic Protection Devices

Peripheral Embolic Protection Devices Pipeline Market Territories Outlook (2024)

  • The United States
  • Europe
  • Global
  • Israel

Peripheral Embolic Protection Devices Pipeline Market Regulatory Paths Outlook (2024)

  • PMA
  • CE
  • 510(k)
  • MDL
  • NMPA

Scope

This report provides:

  • Extensive coverage of the peripheral embolic protection devices under development.
  • An exhaustive list of major pipeline products and their details, including product description, licensing and collaboration details, and other developmental activities.
  • Reviews of major players involved in the development of peripheral embolic protection devices and lists all their pipeline projects.
  • Coverage of pipeline products based on various stages of development ranging from early development to approved/issued stage.
  • Key clinical trial data of ongoing clinical trials specific to pipeline products.
  • Recent developments in the segment/industry.

Reasons to Buy

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies.
  • Identify emerging players with potentially strong product portfolios and create effective counter strategies to gain a competitive advantage.
  • Identify and understand important and diverse types of peripheral embolic protection devices under development.
  • Develop market-entry and market-expansion strategies.
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline.
  • Carry out an in-depth analysis of the product’s current stage of development, territory, and estimated launch date.

Abbott Vascular Inc
AorticLab Sarl
APT Medical Inc
Artio Medical
Avantec Vascular Corp
Cardio-Flow Ltd.
Cardiovascular Systems Inc
Emboline, Inc.
Ev3 Inc
Filterlex Medical Ltd
HeMo Bioengineering Ltd
Innovative Cardiovascular Solutions, LLC
Innovia LLC
InspireMD Inc
Instylla Inc
Javelin Medical Ltd
Keystone Heart Ltd
Marblehead Medical LLC
MicroPort CardioFlow Medtech Corp
MicroPort Scientific Corp
MIV Therapeutics Inc
Neurosonix Ltd.
NewMed Medical Co Ltd
University of Minnesota

Table of Contents

|1 Table of Contents 3

|1.1 List of Tables 5

|1.2 List of Figures 7

2 Introduction 8

2.1 Peripheral Embolic Protection Devices Overview 8

3 Products under Development 9

3.1 Peripheral Embolic Protection Devices – Pipeline Products by Stage of Development 9

3.2 Peripheral Embolic Protection Devices – Pipeline Products by Segment 10

3.3 Peripheral Embolic Protection Devices – Pipeline Products by Territory 11

3.4 Peripheral Embolic Protection Devices – Pipeline Products by Regulatory Path 12

3.5 Peripheral Embolic Protection Devices – Pipeline Products by Estimated Approval Date 13

3.6 Peripheral Embolic Protection Devices – Ongoing Clinical Trials 14

4 Peripheral Embolic Protection Devices – Pipeline Products under Development by Companies 15

4.1 Peripheral Embolic Protection Devices Companies – Pipeline Products by Stage of Development 15

4.2 Peripheral Embolic Protection Devices – Pipeline Products by Stage of Development 17

5 Peripheral Embolic Protection Devices Companies and Product Overview 18

5.1 Abbott Vascular Inc Company Overview 18

5.1.1 Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview 18

5.2 AorticLab Sarl Company Overview 19

5.2.1 AorticLab Sarl Pipeline Products & Ongoing Clinical Trials Overview 19

5.3 APT Medical Inc Company Overview 20

5.3.1 APT Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 20

5.4 Artio Medical Company Overview 21

5.4.1 Artio Medical Pipeline Products & Ongoing Clinical Trials Overview 21

5.5 Avantec Vascular Corp Company Overview 24

5.5.1 Avantec Vascular Corp Pipeline Products & Ongoing Clinical Trials Overview 24

5.6 Cardio-Flow Ltd. Company Overview 25

5.6.1 Cardio-Flow Ltd. Pipeline Products & Ongoing Clinical Trials Overview 25

5.7 Cardiovascular Systems Inc Company Overview 26

5.7.1 Cardiovascular Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 26

5.8 Emboline, Inc. Company Overview 27

5.8.1 Emboline, Inc. Pipeline Products & Ongoing Clinical Trials Overview 27

5.9 Ev3 Inc Company Overview 30

5.9.1 Ev3 Inc Pipeline Products & Ongoing Clinical Trials Overview 30

5.10 Filterlex Medical Ltd Company Overview 31

5.10.1 Filterlex Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview 31

5.11 HeMo Bioengineering Ltd Company Overview 32

5.11.1 HeMo Bioengineering Ltd Pipeline Products & Ongoing Clinical Trials Overview 32

5.12 Innovative Cardiovascular Solutions, LLC Company Overview 34

5.12.1 Innovative Cardiovascular Solutions, LLC Pipeline Products & Ongoing Clinical Trials Overview 34

5.13 Innovia LLC Company Overview 37

5.13.1 Innovia LLC Pipeline Products & Ongoing Clinical Trials Overview 37

5.14 InspireMD Inc Company Overview 38

5.14.1 InspireMD Inc Pipeline Products & Ongoing Clinical Trials Overview 38

5.15 Instylla Inc Company Overview 41

5.15.1 Instylla Inc Pipeline Products & Ongoing Clinical Trials Overview 41

5.16 Javelin Medical Ltd Company Overview 44

5.16.1 Javelin Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview 44

5.17 Keystone Heart Ltd Company Overview 47

5.17.1 Keystone Heart Ltd Pipeline Products & Ongoing Clinical Trials Overview 47

5.18 Marblehead Medical LLC Company Overview 48

5.18.1 Marblehead Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 48

5.19 MicroPort CardioFlow Medtech Corp Company Overview 49

5.19.1 MicroPort CardioFlow Medtech Corp Pipeline Products & Ongoing Clinical Trials Overview 49

5.20 MicroPort Scientific Corp Company Overview 50

5.20.1 MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 50

5.21 MIV Therapeutics Inc Company Overview 51

5.21.1 MIV Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 51

5.22 Neurosonix Ltd. Company Overview 52

5.22.1 Neurosonix Ltd. Pipeline Products & Ongoing Clinical Trials Overview 52

5.23 NewMed Medical Co Ltd Company Overview 53

5.23.1 NewMed Medical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 53

5.24 University of Minnesota Company Overview 54

5.24.1 University of Minnesota Pipeline Products & Ongoing Clinical Trials Overview 54

6 Peripheral Embolic Protection Devices- Recent Developments 55

6.1 Jul 30, 2024: Silk Road Medical Celebrates Milestone of 100,000 Transcarotid Artery Revascularization (TCAR) Procedures 55

6.2 Jul 02, 2024: Penumbra Schedules Second Quarter 2024 Earnings Release and Conference Call for July 30, 2024 55

6.3 Jun 13, 2024: Medtronic Confirms Global Layoffs 56

6.4 May 14, 2024: Instylla Completes Enrollment of Landmark Hypervascular Tumor Pivotal Study 56

6.5 Apr 02, 2024: Silk Road Medical Strengthens TCAR Portfolio with Launch of ENROUTE Transcarotid Neuroprotection System PLUS 56

6.6 Mar 12, 2024: Emboline Announces That the First One Hundred Patients Have Been Treated in the IDE Study of the Emboliner Full-Body Embolic Protection Catheter to Minimize Stroke Risk From TAVR 57

6.7 Mar 12, 2024: Medtronic To Present At Barclays Global Healthcare Conference 58

6.8 Mar 04, 2024: Rapid Medical Receives DeNovo Clearance for BraidE Embolization Assist Device 58

6.9 Feb 28, 2024: Boston Scientific Raises $2.2B to Support Purchase of California Medical Device Company 58

6.10 Feb 23, 2024: Edwards Lifesciences to Present at the 44th Annual TD Cowen Healthcare Conference 58

6.11 Feb 23, 2024: Medical Tech Leader, Boston Scientific (BSX), Announces Notes Offering 58

6.12 Feb 12, 2024: InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard Neuroprotection System 58

6.13 Jan 05, 2024: Boston Scientific Announces Conference Call Discussing Fourth Quarter 2023 Results 59

6.14 Dec 20, 2023: InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard Neuroprotection System 59

6.15 Nov 15, 2023: New Published Study Demonstrates Safety and Feasibility of Filterlex Medical’s CAPTIS Device in Providing Embolic Protection During TAVR 60

6.16 Oct 18, 2023: Edwards Lifesciences to Host Earnings Conference Call on October 25, 2023 60

6.17 Aug 28, 2023: Edwards Lifesciences to Present at the 2023 Wells Fargo Healthcare Conference 60

7 Appendix 61

7.1 Methodology 61

7.2 About GlobalData 64

7.3 Contact Us 64

7.4 Disclaimer 64

Table

Peripheral Embolic Protection Devices – Pipeline Products by Stage of Development 9

Peripheral Embolic Protection Devices – Pipeline Products by Segment 10

Peripheral Embolic Protection Devices – Pipeline Products by Territory 11

Peripheral Embolic Protection Devices – Pipeline Products by Regulatory Path 12

Peripheral Embolic Protection Devices – Pipeline Products by Estimated Approval Date 13

Peripheral Embolic Protection Devices – Ongoing Clinical Trials 14

Peripheral Embolic Protection Devices Companies – Pipeline Products by Stage of Development 15

Peripheral Embolic Protection Devices – Pipeline Products by Stage of Development 17

Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview 18

Emboshield Pro Rapid Exchange Embolic Protection System (Generation 5) – Product Status 18

Emboshield Pro Rapid Exchange Embolic Protection System (Generation 5) – Product Description 18

AorticLab Sarl Pipeline Products & Ongoing Clinical Trials Overview 19

EMBRACE – Product Status 19

EMBRACE – Product Description 19

APT Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 20

Distal Embolic Protection System – Product Status 20

Distal Embolic Protection System – Product Description 20

Artio Medical Pipeline Products & Ongoing Clinical Trials Overview 21

Aneura Embolization Device – Product Status 21

Aneura Embolization Device – Product Description 21

Blockstent Microcatheter – Product Status 22

Blockstent Microcatheter – Product Description 22

Solus Flex Embolization Device – Product Status 22

Solus Flex Embolization Device – Product Description 23

Avantec Vascular Corp Pipeline Products & Ongoing Clinical Trials Overview 24

Peripheral Embolization Device – Product Status 24

Peripheral Embolization Device – Product Description 24

Cardio-Flow Ltd. Pipeline Products & Ongoing Clinical Trials Overview 25

EmboPRO EPD – Product Status 25

EmboPRO EPD – Product Description 25

Cardiovascular Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 26

WIRION EPD System – LE Atherectomy – Product Status 26

WIRION EPD System – LE Atherectomy – Product Description 26

Emboline, Inc. Pipeline Products & Ongoing Clinical Trials Overview 27

Emboliner – Product Status 27

Emboliner – Product Description 27

Emboline, Inc. – Ongoing Clinical Trials Overview 28

Emboliner – Protect the Head to Head: A Safety and Efficacy Assessment of the Emboliner Embolic Protection Device 29

Emboliner – Safety and Technical Performance Evaluation of the Emboliner Embolic Protection Device: A New Zealand Experience 29

Ev3 Inc Pipeline Products & Ongoing Clinical Trials Overview 30

RockHawk With SpiderFX Embolic Protection Device – Product Status 30

RockHawk With SpiderFX Embolic Protection Device – Product Description 30

Filterlex Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview 31

Captis – Product Status 31

Captis – Product Description 31

HeMo Bioengineering Ltd Pipeline Products & Ongoing Clinical Trials Overview 32

Carotid Embolic Protection Device – Product Status 32

Carotid Embolic Protection Device – Product Description 32

Carotid Umbrella – Product Status 33

Carotid Umbrella – Product Description 33

Innovative Cardiovascular Solutions, LLC Pipeline Products & Ongoing Clinical Trials Overview 34

EMBLOK Embolic Protection System – Product Status 34

EMBLOK Embolic Protection System – Product Description 34

Innovative Cardiovascular Solutions, LLC – Ongoing Clinical Trials Overview 35

EMBLOK Embolic Protection System – A Prospective, Randomized, Multicenter Evaluation of the Safety and Effectiveness of the EMBLOK Embolic Protection System During Transcatheter Aortic Valve Replacement 36

Innovia LLC Pipeline Products & Ongoing Clinical Trials Overview 37

Permanently Implantable Embolic Balloon – Product Status 37

Permanently Implantable Embolic Balloon – Product Description 37

InspireMD Inc Pipeline Products & Ongoing Clinical Trials Overview 38

SwitchGuard Neuroprotection System – Product Status 38

SwitchGuard Neuroprotection System – Product Description 38

InspireMD Inc – Ongoing Clinical Trials Overview 39

SwitchGuard Neuroprotection System – A Study to Evaluate the Efficacy of SwitchGuard Neuroprotection System in Transcarotid Artery Revascularization Procedures 40

Instylla Inc Pipeline Products & Ongoing Clinical Trials Overview 41

Embrace Hydrogel Embolic System – Product Status 41

Embrace Hydrogel Embolic System – Product Description 41

Instylla Inc – Ongoing Clinical Trials Overview 42

Embrace Hydrogel Embolic System – A Prospective Multicenter Single-Arm Staged Study to Evaluate the Safety and Effectiveness of Embrace Hydrogel Embolic For Transcatheter Embolization of Arterial Bleeding in Solid Organs and Peripheral Arteries 43

Embrace Hydrogel Embolic System – Randomized Multi-center, Subject and Evaluator Blinded, Parallel-group Study to Evaluate the Safety and Effectiveness of the Instylla Hydrogel Embolic System (HES) Compared with Standard of Care Transcatheter Arterial Embolization (TAE) / Transcatheter Arterial Chemoembolization (cTACE) for Vascular Occlusion of Hypervascular Tumors: A Pivotal Study 43

Javelin Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview 44

Vine – Product Status 44

Vine – Product Description 44

Javelin Medical Ltd – Ongoing Clinical Trials Overview 45

Vine – Carotid Artery Implant for Trapping Upstream Emboli (CAPTURE 2) for Preventing Stroke in Atrial Fibrillation Patients Taking Oral Anticoagulants 46

Keystone Heart Ltd Pipeline Products & Ongoing Clinical Trials Overview 47

TriGUARD3 Cerebral Embolic Protection Device – Product Status 47

TriGUARD3 Cerebral Embolic Protection Device – Product Description 47

Marblehead Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 48

FFRACAS Device – Product Status 48

FFRACAS Device – Product Description 48

MicroPort CardioFlow Medtech Corp Pipeline Products & Ongoing Clinical Trials Overview 49

Embolic Protection Device – TAVI – Product Status 49

Embolic Protection Device – TAVI – Product Description 49

MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 50

Arterial Micro-Embolic Filter – Product Status 50

Arterial Micro-Embolic Filter – Product Description 50

MIV Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 51

Aortic Embolic Protection Device – Product Status 51

Aortic Embolic Protection Device – Product Description 51

Neurosonix Ltd. Pipeline Products & Ongoing Clinical Trials Overview 52

Protection Collar – Product Status 52

Protection Collar – Product Description 52

NewMed Medical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 53

Cerebral Embolic Protection Device – Product Status 53

Cerebral Embolic Protection Device – Product Description 53

University of Minnesota Pipeline Products & Ongoing Clinical Trials Overview 54

Embolic Protection Device – Product Status 54

Embolic Protection Device – Product Description 54

Glossary 63

Figures

Peripheral Embolic Protection Devices – Pipeline Products by Stage of Development 9

Peripheral Embolic Protection Devices – Pipeline Products by Segment 10

Peripheral Embolic Protection Devices – Pipeline Products by Territory 11

Peripheral Embolic Protection Devices – Pipeline Products by Regulatory Path 12

Peripheral Embolic Protection Devices – Pipeline Products by Estimated Approval Date 13

Peripheral Embolic Protection Devices – Ongoing Clinical Trials 14

Frequently asked questions

Peripheral Embolic Protection Devices Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies standard reports
Currency USD
$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Peripheral Embolic Protection Devices Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Peripheral Embolic Protection Devices Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies in real time.

  • Access a live Peripheral Embolic Protection Devices Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.